Gilead to Test an Inhaled Version of Remdesivir
Gilead Sciences (NASDAQ: GILD) CEO Daniel O'Day announced on Monday that his company will soon begin a phase 1 clinical trial evaluating an inhaled version of remdesivir as a treatment for patients with COVID-19. The biotech plans to screen healthy volunteers beginning this week with the goal of initiating clinical testing in early-stage COVID-19 patients in August.
Currently, remdesivir is administered to hospitalized COVID-19 patients through intravenous infusion. Gilead thinks that an inhaled version of the drug that patients could take using a nebulizer would be easier to administer outside a hospital setting, and could be given to patients earlier in the course of the illness.
Image source: Getty Images.
Source Fool.com
